CONCORD, Mass., Nov. 9, 2016 /PRNewswire/ -- ActiveCareŽ, a trademark brand of Medical Compression Systems (MCS),
ActiveCareŽ is a platform of smart-compression treatment alternatives to anticoagulant drugs in the prevention of deep vein thrombosis (DVT), costly complications and readmissions in total joint replacement procedures. Those interested in learning more are invited to learn more about ActiveCareŽ at conference booth #1213.
Venous thromboembolism (VTE) is a common complication following total joint replacement procedures. This condition includes both DVT, a blood clot in a deep vein in the lower extremities; and pulmonary embolism (PE), where the blood clot becomes dislodged and migrates to the lungs.
An estimated 1 million hip and knee replacements are performed in the U.S. annually, primarily in patients over the age of 50 years old. Studies have found that this age group is disproportionately affected by VTE.
The new results will showcase the platform's effectiveness at reducing the risk of VTE while simultaneously reducing the risk of costly readmissions and complications, such as major bleeding and infections often associated with anticoagulants together with increased patient satisfaction.
Gerry Feldman, CEO and Chairman of MCS, believes that greater focus should be placed on the prevention of VTE in orthopedic patients:
"VTE is a patient condition currently being targeted by the CMS Hospital Readmission Program. In order to support these measures, greater coverage of devices proven to prevent blood clots - including Intermittent Pneumatic Compression Devices - should be eligible for reimbursement under Medicare Part B."
Moreover, Mr. Feldman also said that VTE prophylaxis must not only occur during and after procedures in healthcare facilities, but emphasis needs to also be placed on ensuring patients are protected with IPCD for use upon discharge from hospital, during the critical period of at-home post-surgical recovery.
The American Association of Hip and Knee Surgeons' 26th Annual meeting is being held in Dallas, Texas from November 10-13, 2016. It will address a broad array of scientific topics, such as implant design, outcomes, surgical techniques and complications of primary and revision total joint arthroplasty (TJA) for hip and knee surgeons.
ActiveCareŽ is a brand of MCS, a leader in non-invasive smart compression therapy devices that enhance arterial, venous and lymphatic circulation and create new clinical and economic value compared to available alternatives. MCS is the first and only company to offer the healthcare market a new class of therapy which combines MCS's patented Synchronized Flow Technology (ActiveCareŽ + S.F.T.) device, proven to effectively prevent DVT with no risk of major bleeding complications, thus improving the healthcare standard.
ActiveCareŽ fully meets the American College of Chest Physicians' Evidence-Based Clinical Practice Guidelines (ACCP 2012) to prevent DVT after total joint replacement for the duration of treatment, from hospital to home.
About MCS Medical Compression Systems
Founded in 1997, MCS Medical Compression Systems (Ltd.) is an Israeli publicly traded company on the Tel Aviv Stock Exchange (TASE: MDCL). MCS Inc., the company's subsidiary, is located in the USA. For more information, please visit http://www.activecare.mcsmed.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/preventing-blood-clots-costly-complications-or-readmissions-in-orthopedic-patients-300359136.html
SOURCE Medical Compression Systems
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All